Are you receiving initial treatment for non-small cell lung cancer or invasive squamous cell carcinoma of the head and neck and want to participate in research that aims to improve treatment and care of future patients with the same diagnosis? If so, you may be able to participate in a study for an investigational blood test to predict whether your cancer will come back.

In this study, we want to learn more about the safety and effectiveness of using a personalized vaccine with a drug called pembrolizumab for the treatment of non‐small cell lung cancer (NSCLC) and squamous cell cancer of the head and neck (SCCHN).

We are doing a study to help us adapt a physical activity program for adults with intellectual disabilities. We are looking for adults with intellectual disabilities, parents/caregivers, support staff, and exercise professionals to complete a survey and take part in interviews or focus groups to provide feedback on a physical activity program. The program includes weekly group fitness meetings, one-to-one coaching meetings, and an app to support setting, monitoring, and achieving exercise goals.

People with SCLC are usually treated with a combination of drugs that are approved by the Food and Drug Administration (FDA). However, these drugs may no longer be working in controlling your cancer or may not be a good treatment option for you. This study uses an investigational combination of drugs, trilaciclib and lurbinectedin. The purpose of this study is to test whether trilaciclib helps minimize the side effects of lurbinectedin and therefore improve the safety of lurbinectedin for the treatment of small cell lung cancer (SCLC).

Are you between 18 and 45 years of age and diagnosed with multiple sclerosis, without MS relapses within the past year? Are you currently prescribed with MS medication? If so, you may be able to participate in a research study examining whether a switch to a high-efficacy medication- Ofatumumab, would work better for you than your current treatment.

In the EAGLE study we want to find out if the study drug, OM-85, helps your child's recurrent wheezing better than other drugs or other types of treatments that are currently available and approved in the US market. The study drug is a marketed product in several countries worldwide but not yet in the US.

The purpose of this study is to determine how people with PD learn to improve their walking. Participants will enroll in 12 walking training sessions, either with or without a metronome that beeps while you walk. The metronome tempo is set to target certain aspects of your walking. We will test your walking before, after, and at 3 months following all training.

This is a research study to investigate how collecting information about treatment-related side effects directly from patients can help manage the side effects associated with certain oral chemotherapies in patients with metastatic renal cell carcinoma.

Have you been diagnosed with Leukemia and looking for another treatment option? Do you have Myelofibrosis (MF), myelodysplastic syndrome (MDS) and /or myelodysplastic/myeloproliferative overlap syndrome (MDS/MPN)? You may be able to take part in this study to find out the safety and effectiveness of a study drug.

In this study, we want to learn more about how stress related to COVID-19 can affect behaviors and the way that genes work (epigenetics) in healthcare workers. This study focuses on healthcare workers because they are in the frontline of the pandemic.